Canada's Virogin raises $120m led by China Life; to use proceeds for Shanghai R&D centre

Canada's Virogin raises $120m led by China Life; to use proceeds for Shanghai R&D centre

Virogin Biotech, a Vancouver, Canada-based developer of next-generation oncolytic virus (OV) therapeutics, has raised over $120 million in a Series D2 round of financing as the company looks to build its global R&D centre in China’s Shanghai city.

Already backed by a group of largely China-based firms, Virogin again roped in Chinese investors in the Series D2 round. The transaction was led by the Chinese insurer China Life’s healthcare industry investment fund, China Life Healthcare Fund.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter